Prothena Corporation PLC
NASDAQ:PRTA

Watchlist Manager
Prothena Corporation PLC Logo
Prothena Corporation PLC
NASDAQ:PRTA
Watchlist
Price: 15.4 USD 0.46% Market Closed
Market Cap: 828.7m USD
Have any thoughts about
Prothena Corporation PLC?
Write Note

Prothena Corporation PLC
Net Issuance of Common Stock

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Prothena Corporation PLC
Net Issuance of Common Stock Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Common Stock CAGR 3Y CAGR 5Y CAGR 10Y
Prothena Corporation PLC
NASDAQ:PRTA
Net Issuance of Common Stock
$2.1m
CAGR 3-Years
-78%
CAGR 5-Years
60%
CAGR 10-Years
-37%
Alkermes Plc
NASDAQ:ALKS
Net Issuance of Common Stock
-$179.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amarin Corporation PLC
NASDAQ:AMRN
Net Issuance of Common Stock
$224k
CAGR 3-Years
-70%
CAGR 5-Years
-80%
CAGR 10-Years
-20%
No Stocks Found

Prothena Corporation PLC
Glance View

Market Cap
828.7m USD
Industry
Biotechnology

Prothena Corp. Plc is a clinical-stage neuroscience company. The firm is engaged in the protein dysregulation and a pipeline of therapeutics for devastating neurodegenerative and rare peripheral amyloid diseases. The company is advancing a pipeline of therapeutic candidates around neurological dysfunction and the biology of misfolded proteins. The firm's clinical pipeline of antibody-based product candidates targets a range of indications, including Birtamimab for the treatment of amyloid light-chain (AL) amyloidosis; prasinezumab for the treatment of Parkinson’s disease and other related synucleinopathies; and PRX004, for the treatment of Transthyretin amyloidosis (ATTR). The firm's pipeline also includes late-preclinical-stage programs targeting proteins implicated in neurological diseases including tau and amyloid beta (Aβ) for the treatment of Alzheimer’s disease and other neurodegenerative disorders, and TDP-43 for the treatment of amyotrophic lateral sclerosis.

PRTA Intrinsic Value
36.55 USD
Undervaluation 58%
Intrinsic Value
Price

See Also

What is Prothena Corporation PLC's Net Issuance of Common Stock?
Net Issuance of Common Stock
2.1m USD

Based on the financial report for Sep 30, 2024, Prothena Corporation PLC's Net Issuance of Common Stock amounts to 2.1m USD.

What is Prothena Corporation PLC's Net Issuance of Common Stock growth rate?
Net Issuance of Common Stock CAGR 10Y
-37%

Over the last year, the Net Issuance of Common Stock growth was -99%. The average annual Net Issuance of Common Stock growth rates for Prothena Corporation PLC have been -78% over the past three years , 60% over the past five years , and -37% over the past ten years .

Back to Top